Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 162 across all filing types
Latest filing 2014-04-11 Earnings Release
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 95% confidence The document is a press release titled 'Résultats annuels 2013' (Annual Results 2013) for IntegraGen. It provides a summary of financial performance, including income statements and balance sheet data for the fiscal year ending December 31, 2013. While it contains financial data, it is structured as a corporate press release announcing annual results rather than a full statutory Annual Report (10-K). According to the classification rules, this type of document, which provides a summary of annual financial results, is classified as an Earnings Release (ER). FY 2013
2014-04-11 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 90% confidence The document is a press release announcing a collaborative agreement between IntegraGen and Pfizer regarding a molecular signature for hepatocellular carcinoma. It details a business development/partnership, not a mandatory regulatory filing like a 10-K, an earnings report (ER), or a formal capital structure change (CAP/SHA). Since it is an announcement regarding a specific business development (a collaboration/agreement), and there isn't a specific code for 'Business Development Announcement', the most appropriate general category for significant, non-standard corporate news that doesn't fit other specific financial/regulatory types is 'Regulatory Filings' (RNS) as a catch-all for important corporate news releases, or potentially 'LTR' if the agreement involved significant legal/licensing terms, but RNS is safer for a general press release of this nature. Given the options, and that it is a press release announcing a strategic agreement, RNS (Regulatory Filings/General Announcement) is the best fit among the provided codes, as it is not a core financial report or a specific insider/governance filing.
2014-04-03 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – POUR DIFFUSION IMMEDIATE" (Press Release – For Immediate Release). It announces a collaboration agreement between IntegraGen and Pfizer regarding molecular signature evaluation for hepatocellular carcinoma. This type of announcement, detailing business developments, partnerships, or significant operational news outside of mandatory financial reporting forms (like 10-K or ER), is best classified as a general Regulatory Filing (RNS) or potentially a specific business update if a better fit existed. Since it is a press release announcing a strategic business development (collaboration/partnership), and there is no specific code for 'Partnership Announcement', RNS (Regulatory Filings / General Announcements) is the most appropriate fallback category for non-standard, immediate corporate news releases. It is not an Earnings Release (ER), nor a formal financial report (10-K, IR).
2014-04-03 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'COMMUNIQUE DE PRESSE – POUR DIFFUSION IMMEDIATE' (Press Release – For Immediate Release). It announces a strategic partnership and operational setup between two entities (IntegraGen and Gustave Roussy) regarding high-throughput sequencing technology. This type of announcement, detailing business developments, partnerships, or strategic initiatives, is typically classified as a general regulatory announcement or a press release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is not a formal financial report, a management discussion, or a specific corporate action like a dividend or share issue, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere.
2014-03-24 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 94% confidence The document is explicitly labeled as a "PRESS RELEASE – FOR IMMEDIATE DIFFUSION" and announces a specific business development: the setup of a High-Throughput Clinical Sequencing Unit between IntegraGen and Gustave Roussy. This is not a standard regulatory filing (like 10-K, AR, IR), nor is it a transcript, dividend notice, or management change announcement. It is a corporate announcement detailing a strategic partnership and operational setup. Since there is no specific category for 'Strategic Partnership Announcement' or 'Business Development Update', and it is a formal announcement intended for immediate release to the public/media, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous official announcements that don't fit the highly specific financial report types listed.
2014-03-24 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – POUR DIFFUSION IMMEDIATE" (Press Release – For Immediate Release). It announces the publication of a scientific study by IntegraGen in a journal ('Frontiers in Genetics') regarding autism genetics. This type of announcement, which communicates recent news, results, or the availability of information (like a study or report), fits best under the general category for regulatory or corporate announcements that aren't specific financial reports (10-K, IR, ER) or management changes (MANG). Since it is a press release announcing a scientific finding and referencing a published study, and it doesn't fit the specific definitions for ER, AR, LTR, or RPA (which usually announces the *release* of a formal report), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate communications. It is not an Earnings Release (ER) as it discusses research, not financial performance. It is not an Audit Report (AR). It is not an Investor Presentation (IP) as it is a press release format. It is not a Report Publication Announcement (RPA) because it is announcing the *content* of the study's publication, not just the fact that a formal company report is being released.
2014-02-21 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.